Tiziana's Intranasal Foralumab Shows Promise in Progressive MS Study
Event summary
- Tiziana Life Sciences published peer-reviewed results in Neurology Neuroimmunology & Neuroinflammation for intranasal foralumab in non-active secondary progressive multiple sclerosis (na-SPMS).
- The open-label study showed stabilization of EDSS scores in all 10 patients, with 3 of 4 patients treated for 12 months demonstrating improvement.
- No serious or severe treatment-related adverse events occurred, and fatigue improved in 6 out of 10 patients.
- TSPO-PET imaging revealed significant reductions in microglial activation, and single-cell RNA sequencing demonstrated sustained increases in regulatory T cells (Tregs).
- Tiziana is advancing intranasal foralumab in an ongoing Phase 2 trial with top-line data expected in the first half of 2026.
The big picture
Tiziana's publication marks a critical validation of intranasal foralumab's potential in treating progressive MS, an area with significant unmet needs. The study's integration of advanced imaging and immune profiling could set a new standard for neuroinflammatory disease research. With ongoing Phase 2 trials, the company is positioning itself at the forefront of a shift toward targeted, non-systemic immunotherapies in neurology.
What we're watching
- Clinical Validation
- Whether the peer-reviewed results will accelerate regulatory discussions or partnerships for intranasal foralumab.
- Market Differentiation
- How Tiziana positions foralumab against existing MS therapies, leveraging its unique mucosal tolerance mechanism.
- Execution Risk
- The pace at which Tiziana can translate these findings into broader clinical adoption and commercialization.
Related topics